Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VHB937 in Amyotrophic Lateral Sclerosis (ALS)
NCT06643481Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2024
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 2 trial of VHB937 in amyotrophic lateral sclerosis (ALS), sponsored by Novartis. Started Oct 2024; status: active, not recruiting.
02
Drugs
VHB937
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06643481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06643481.